Verrica Pharmaceuticals
VRCA
57 hedge funds and large institutions have $21.8M invested in Verrica Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 16 closing their positions.
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
12% more funds holding
Funds holding: 51 → 57 (+6)
0.89% more ownership
Funds ownership: 3.23% → 4.12% (+0.89%)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
11% less call options, than puts
Call options by funds: $34K | Put options by funds: $38K
70% less capital invested
Capital invested by funds: $72.1M → $21.8M (-$50.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$7.18M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.79M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.79M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$2.26M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.46M |
| 2 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$2.91M |
| 3 |
BlackRock
New York
|
-$2.86M |
| 4 |
ACM
Altium Capital Management
New York
|
-$794K |
| 5 |
State Street
Boston,
Massachusetts
|
-$745K |
VRCA Hedge Fund Activity: Q2 2022 in Review
57 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2022, worth a combined $21.8M — down 70% from $72.1M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VRCA positions and 16 closed out — a net gain of 7 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $7.18M. The largest seller was Morgan Stanley, cutting an estimated $3.46M.
- 57 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2022, up from 51 in Q1 2022.
- Funds reported $21.8M of Verrica Pharmaceuticals stock for Q2 2022, down 70% quarter-over-quarter.
- 23 funds opened new Verrica Pharmaceuticals positions in Q2 2022 and 16 closed out, a net change of +7 holders.
- The largest Verrica Pharmaceuticals buyer in Q2 2022 was Perceptive Advisors, an estimated $7.18M added.
- The largest Verrica Pharmaceuticals seller in Q2 2022 was Morgan Stanley, an estimated $3.46M sold.
Based on aggregated 13F filings for Q2 2022.